CompanyNCELNasdaqZurich

NewcelX Ltd.

NewcelX develops stem-cell-derived therapies for Type 1 Diabetes.

SEC EDGAR ClinicalTrials.gov newcelx.com

6-KSep 18Latest SEC filing, period to Jun 30

Aug 24Latest story

August 2026

NewcelX Ltd. files Form D for private placement raising $2.94 million

Aug 24FinancingNewcelX Ltd.

July 2026

NewcelX prices $1.4 million private placement at 20% premium

Jul 31FinancingNewcelX Ltd.

NewcelX names diabetes cure researcher Dr. Camillo Ricordi to scientific advisory board

Jul 8PeopleNewcelX Ltd.